LaurusLabs climbs 6% on USFDA approval

Shares of Laurus Labs climbed 6 percent on Thursday after the pharma company received USFDA approval for a generic drug used in the treatment of diabetes.
The stock rose 5.84 percent to hit a high of Rs 464.35 on the BSE.

For Real Time News & Trading Trends Keep Liking Epic Research Limited

For more information on Equity Market News Call us ✆ – 0731-6642300 or Visit http://www.epicresearch.co

Connect with our social media sites

Facebook

Twitter

YouTube

Pinterest

Linkedin

Google+

Follow @Epic_Research